Brighter’s main Actiste patent granted in India – can support the growing biosimilar industry
Brighter's main patent for Actiste® has been granted in India, a front-running market in the biosimilar industry.
“India’s growing biosimilars landscape, a USD multi-billion market addressing the pressing global need for more cost-efficient drugs, creates an opportunity for Brighter to support pharmaceutical companies in their drug development by providing highly valuable data related to e.g. drug efficiency,” says Henrik Norström, Brighter’s CEO.
Biosimilars presents a $240 Billion global opportunity for Indian Pharmaceuticals Industry while domestic market is expected to cross $40 Billion by 2030, according to ASSOCHAM (Associated Chambers of Commerce of India).
Actiste, based on patented technology for collecting data on specified biomarkers and injected volumes of drugs, is the world's first complete IoT care solution for monitoring and treating insulin-dependent diabetes. The unit brings together and combine all the necessary functions for diabetes care – blood sampling, blood glucose measurement and drug injection – in a single connected device.
With state-of-the-art eSIM technology, Actiste has global out-of-the-box connectivity, making it completely independent of other devices to utilize and share health and treatment data. Actiste received two CE-marks in September 2019 - one for MDD and one for IVDD.
Approximately 77 million people with diabetes lives in the region according to International Diabetes Federation and the number is expected to increase by 70% over the next 20 years.
For further information, please contact:
Henrik Norström, CEO
+46 733 40 30 45
Brighter’s Certified Adviser on Nasdaq OMX First North is Eminova Fondkommission AB, +46 (0)8 – 684 211 10, email@example.com, www.eminova.se.
About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – improving quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award.
The Company's shares are listed on Nasdaq First North Growth Market/BRIG.